The Agenda

Agenda – What’s on when

Friday – May 16, 2025

7:00 – 7:55

Registration and Check-in          Light Breakfast Served

7:55 – 8:00

Genomic Workshop – Welcome and Learning Objectives

Scientific Program Committee

Maher Albitar, MD – CEO, Genomic Testing Cooperative

Gustavo Rivero, MD, – Director, Translational Research for Hematologic Malignancies, Tampa General Hospital Cancer Institute

Anne Renteria MD – Site Director, Transplantation & Cellular Therapy Program, Perlmutter Cancer Center, NYU Langone Health

David Swoboda, MD – Director, Leukemia Program, Tampa General Hospital Cancer Institute

8:00 – 9:00

Session Introduction to Myeloid Genomics – Myeloid Malignancies Pathogenesis

Session Chair Introduction

David Swoboda, MD – Director, Leukemia Program, Tampa General Hospital Cancer Institute

8:00-8:15

Evolving Concepts in Myeloid Neoplasm Sequencing

Maher Albitar, MD – CEO, Genomic Testing Cooperative

8:15-8:30

Myeloid and Non-Myeloid Clonal Hematopoiesis

Maher Albitar, MD – CEO, Genomic Testing Cooperative

David Swoboda, MD – Director, Leukemia Program, Tampa General Hospital Cancer Institute

8:30-8:50

Myeloid Germline Predisposition

Maher Albitar, MD – CEO, Genomic Testing Cooperative

Lacey Williams, MD – Assistant Professor, University of North Carolina School of Medicine

9:00 – 10:00

Session 1: Myeloid Leukemogenesis

Session Chair Introduction

Gustavo Rivero, MD – Director, Translational Research for Hematologic Malignancies, Tampa General Hospital Cancer Institute

9:00-9:20

MDS to AML

Maher Albitar, MD – CEO, Genomic Testing Cooperative

Gustavo Rivero, MD – Director, Translational Research for Hematologic Malignancies, Tampa General Hospital Cancer Institute

9:20-10:00

AML-Bioinformatics Pipeline Applicability – 2 Tumor Board Cases

Maher Albitar, MD –  CEO, Genomic Testing Cooperative 

David Swoboda, MD – Director, Leukemia Program, Tampa General Hospital Cancer Institute

10:00-10:15

Coffee Break

10:15-11:30

Session 2: Myelodysplastic Syndrome

Session Chair Introduction

David Sallman, MD – Section Head, Leukemia and Myelodysplastic Syndrome, Moffitt Cancer Center

10:15-10:40

Inherited Bone Marrow Failure – Case Tumor Board

Maher Albitar, MD – CEO, Genomic Testing Cooperative

David Sallman, MD – Section Head, Leukemia and Myelodysplastic Syndrome, Moffitt Cancer Center

10:40-11:00

Low-Risk MDS

Maher Albitar, MD – CEO, Genomic Testing Cooperative

Gustavo Rivero, MD – Director, Translational Research for Hematologic Malignancies, Tampa General Hospital Cancer Institute

11:00-11:30

High-Risk MDS

Maher Albitar, MD – CEO, Genomic Testing Cooperative

David Swoboda, MD – Director, Leukemia Program, Tampa General Hospital Cancer Institute

11:30-11:55

Lunch is being combined with the product theater below 

11:55-12:55

Targeting Telomerase in MDS: A New Frontier

Shyamala Navada, MD – Executive Medical Director, Geron 

13:00 – 14:00

Session 3:  Myeloproliferative Neoplasm

Session Chair Introduction

Iberia Romina Sosa, MD, PhD – Chief, Division of Hematology, Fox Chase Cancer Center

13:00-14:00

MPN Transformation to Blastic Phase

Maher Albitar, MD – CEO, Genomic Testing Cooperative

Iberia Romina Sosa, MD, PhD – Chief, Division of Hematology, Fox Chase Cancer Center

Quinto Gesiotto, MD – Chief Fellow, Hematology/Oncology, Thomas Jefferson University

14:00-14:10

Coffee Break

14:10-15:10

Session 4: Lymphomas

Session Chair Introduction

Eduardo Sotomayor, MD – Executive Director, Tampa General Hospital Cancer Center Institute

14:10-14:40

Diffuse Large B-Cell Lymphoma

Maher Albitar, MD – CEO, Genomic Testing Cooperative

Alan Kerr, II, MD, PhD – Physician Scientist, Hematology/Oncology, Tampa General Hospital Cancer Institute

14:40-15:00

Lymphoma MRD

Maher Albitar, MD – CEO, Genomic Testing Cooperative

Nikesh Shah, MD – Physician Scientist, Hematology/Oncology, Tampa General Hospital Cancer Center Institute

15:00-16:00

Session 5: Multiple Myeloma

Session Chair Introduction

Ivan Borrello, MD – Medical Director, Myeloma, Bone Marrow Transplant and Cell Therapies Program, Tampa General Hospital Cancer Institute

15:00-15:20

The Myeloma Genome

Ivan Borrello, MD – Medical Director, Myeloma, Bone Marrow Transplant and Cell Therapies Program, Tampa General Hospital Cancer Institute

15:20-15:40

Myeloma Tumor Board

Maher Albitar, MD – CEO, Genomic Testing Cooperative

Ivan Borrello, MD – Medical Director, Myeloma, Bone Marrow Transplant and Cell Therapies Program, Tampa General Hospital Cancer Institute

15:40-16:00

Myeloma MRD

David Siegel, MD, PhD – Chief, Myeloma Division, Hackensack Meridian Health

Saturday – May 17, 2025

7:00-7:55

Registration and Check-in          Light Breakfast         

7:55-8:00

Hematologic Malignancies Symposium – Welcome and Learning Objectives

Scientific Program Committee

Gustavo Rivero, MD – Director, Translational Research for Hematologic Malignancies, Tampa General Hospital Cancer Institute

Anne Renteria, MD – Site Director, Transplantation & Cellular Therapy Program, Perlmutter Cancer Center, NYU Langone Health

David Swoboda, MD – Director, Leukemia Program, Tampa General Hospital Cancer Institute

Maher Albitar, MD – CEO, Genomic Testing Cooperative

8:00 – 8:30

Featured Lecture

Session Chair Introduction

Gustavo Rivero, MD – Director, Translational Research for Hematologic Malignancies, Tampa General Hospital Cancer Institute

8:00-8:30

Manipulating the Leukemia Stem Cell Microenvironment

Tiphaine Martin, MEng, PhD – Assistant Professor – Computational Biologists, Bioinformatics & Biostatistics, Icahn School of Medicine at Mount Sinai

8:30-9:20

Session 1: Implementing a Clonal Hematopoiesis Clinic

Session Chair Introduction

Gustavo Rivero, MD – Director, Translational Research for Hematologic Malignancies, Tampa General Hospital Cancer Institute

8:30-8:55

What Important Primary Aims Should be Considered for a CHIP Clinic?

Ludovica Marando, MD, PhD – Assistant Professor, Molecular and Cellular Biology, Baylor College of Medicine

8:55-9:20

How to Integrate CHIP and Atherosclerosis Risk

Dae Hyun Lee, MD – Assistant Professor, Internal Medicine, Cardiovascular Sciences, USF Morsani Center

9:20-10:25

Session 2: Myelodysplastic Syndrome

Session Chair Introduction

9:20-9:40

ICC vs WHO Classification – Pros and Cons

Stephen D. Nimer, MD – Director, Sylvester Comprehensive Cancer Center 

9:40-10:00

Two Questions at Once – Intravenous vs Oral Decitabine and When to Add BCL-2 Inhibitor in High Risk MDS

Guillermo Garcia-Manero, MD – Chief, Section of Myelodysplastic Syndromes, MD Anderson Cancer Center, Houston, TX 

10:00-10:25

Novel Trials in MDS

David Sallman, MD – Section Head, Leukemia and Myelodysplastic Syndrome, Moffitt Cancer Center

10:25-11:30

Session 3: Racial Disparity and Myeloid Malignancies

Session Chair Introduction

Gustavo Rivero, MD – Director, Translational Research for Hematologic Malignancies, Tampa General Hospital Cancer Institute

10:25-10:45

Molecular Basis of Myeloid Malignancies Racial Disparity

Gustavo Rivero, MD – Director, Translational Research for Hematologic Malignancies, Tampa General Hospital Cancer Institute

10:45-11:05

Social and Genomics Interaction in Myeloid Malignancies

Lacey Williams, MD – Assistant Professor, University of North Carolina

11:05-11:30

INF vs JAK2 Inhibitor for Pvera – Why?

Iberia Romina Sosa, MD, PhD – Chief, Division of Hematology, Fox Chase Cancer Center

11:30-11:45

Lunch – This is being combined with the TGH Cancer Institute Sponsored Session Below 11:45-13:00

11:45 – 13:00

Tampa General Hospital Cancer Institute Sponsored Session:

HTLV from Discovery to Genomics

Session Co-Chairs

Eduardo Sotomayor, MD – Executive Director, Tampa General Hospital Cancer Institute

Gustavo Rivero, MD – Director, Translational Research for Hematologic Malignancies, Tampa General Hospital Cancer Institute

11:45-12:10

History of HTLV1 Discovery

Robert C. Gallo, MD – Director, Microbial Oncology Program, Tampa General Hospital Cancer Institute

12:10-12:35

Genomics of HTLV1: Unveiling Novel Targets

Yutaka Tagaya, MD – Assistant Professor, Tampa General Hospital Cancer Institute

12:35-13:00

HTLV-Induced Adult T-Cell Leukemia/Lymphoma

Maher Albitar, MD – CEO, Genomic Testing Cooperative

Alan Kerr, II, MD, PhD – Physician Scientist, Hematology/Oncology, Tampa General Hospital Cancer Institute Institute

13:00-15:25

Session 4: AML Highlights – What Physicians Should Know

Session Chair Introduction

David Swoboda, MD – Director, Leukemia Program, Tampa General Hospital Cancer Institute

13:00-13:25

The AML Epigenome- Recent Advances

Rory Shallis, MD – Assistant Member, Malignant Hematology Department, Moffitt Cancer Center

13:25-13:50

Advances in AML MRD Testing

Manja Meggendorfer, PhD – Head, Molecular Genetics, Munich Leukemia Laboratory

13:50-14:10

How I Manage FLT3 Mutated AML

David Swoboda, MD – Director, Leukemia Program, Tampa General Hospital Cancer Institute

14:10-14:30

How I Manage MLL Rearranged AML

Jeffrey Lancet, MD – Senior Member and Chair, Department of Malignant Hematology,  Moffitt Cancer Center

14:30-14:50

Advances in AML Immunology

Sergio Rutella, MD – Director, Nottingham Trent University John van Geest Cancer Research Centre, United Kingdom

14:50-15:15

Coffee Break

15:15-16:35

Session 5: Cellular Therapy

Session Chair Introduction

Anne Renteria, MD – Site Director, Transplantation & Cellular Therapy Program, Perlmutter Cancer Center, NYU Langone Health

15:15-15:35

Advances in GVHD Prophylaxis

Maher Abdul Hay, MD – Director, Clinical Leukemia Program, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health

15:35-15:55

HLA Matching in Allogeneic Cellular Transplantation

Olga Timofeeva, PhD – Associate Director, UCLA Immunogenetics Center

15:55-16:15

Advances in AML CAR T-cell Therapies

Jingmei Hsu, MD – Director, Cellular Therapy Laboratory, NYU Langone Perlmutter Cancer Center

16:15-16:35

Fitness and Supportive Care in Malignant Hematology for Allo-HCT

Anne Renteria, MD – Site Director, Transplantation & Cellular Therapy Program, Perlmutter Cancer Center, NYU Langone Health

16:35-16:45

Final Remarks

2026 Event Announcement

REGISTRATION
OPEN

SPONSOR

Interested in sponsoring the event? Email Nigel Russell by using the link below!

Tampa General Hospital